News With Approval Pending, Pegcetacoplan Phase 3 Results Mixed by Medscape • 2022/10/03 • 0 Comments With an FDA action date set, investigative complement inhibitor pegcetacoplan showed a signal for improving visual function in geographic atrophy but also a risk for conversion to wet AMD. Medscape Medical News Full Story →